Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for breakthrough chemotherapy-induced vomiting in children
NCT07035821Phase 3Not yet recruiting
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olanzapine in chemotherapy-induced nausea and vomiting (CINV). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
olanzapine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT07035821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035821.